The pandemic of AIDS resulting from HIV-1 infection is particularly devastating in southern Africa. 1 HIV-1 enters target cells through a two-step fusion process in which the CC-motif chemokine receptor 5 (CCR5) serves as a major coreceptor on human CD4 þ T cells. Multiple studies have demonstrated that individuals who are homozygous for the CCR5 deletion mutation (del-32) lack functional CCR5 and are thus highly resistant to HIV-1 infection. [2] [3] [4] [5] CC-motif chemokine ligands (CCL), CCL3 (MIP-1a), CCL4 (MIP-1b) and CCL5 (RANTES), are natural ligands for CCR5; as such they may competitively inhibit binding of the receptor by HIV-1. [6] [7] [8] [9] [10] Variants in CCR2, the gene adjacent to CCR5, have also been reported to be independently associated with HIV-1 infection, progression and transmission.
11 CCL2, the natural ligand for CCR2, may also be an important factor for the HIV-1 transmission. [12] [13] [14] Numerous studies document the influence of CCR5 variants on the HIV-1 transmission, infection and disease progression. However, observations of the impact of the ligands on HIV-1 acquisition and disease control in populations of African ancestry are sparse. To complement our work on the role of the receptor polymorphisms, 11 we examined the associations of single-nucleotide polymorphisms (SNPs) in the CCL genes with HIV-1 heterosexual transmission and disease control in Zambia cohort.
Between 1995 and 2006 in Lusaka, Zambia, more than 10 000 couples were screened for their HIV-1 status in the Zambia-Emory HIV-1 Research Project. The procedures for screening, recruitment, counseling and follow-up visits have been described elsewhere. 15, 16 The study presented here included 567 HIV-1 serodiscordant couples who were followed for at least 9 months between 1996 and 2006. Among these, 240 HIV-1-exposed seronegative (HESN) participants acquired phylogenetically linked HIV-1 (ref. 13) from their donor (index) partners after varying lengths of follow-up (interquartile range: 6-36 months) and 327 HESN participants remained seronegative during the study intervals. Non-genetic factors, including age, gender, index partner viral load (VL), genital ulcer or inflammation in either partner, and male circumcision were treated as covariates, as established in earlier analyses of HIV-1 transmission within the study population. 11, 17, 18 In the absence of selection for pre-exposure time before enrollment, the observed genetic associations with rate of HIV-1 transmission should not have been systematically affected by duration of pre-exposure. On the other hand, because non-transmitting couples had higher frequencies of non-genetic risk factors, the observed transmission rates were higher than the overall rates in the entire cohort of discordant couples. Overall, the annual HIV-1 seroincidence (7-9 events per 100 person-years) among Zambian couples was reduced by one-half to two-thirds as a result of voluntary testing and counseling. 1 We assessed recognized SNPs reported in dbSNP to map between 1 kb upstream and 500 bp downstream of the four candidate CCL genes (CCL2, CCL3, CCL4 and CCL5). Each SNP included in the analysis met at least one of the following criteria: (1) encodes a change in the amino-acid sequence of the ligand; (2) occurs at a transcription-binding site, an intron/exon boundary site, an alternative splicing site, or in the promoter region or 3 0 untranslated region; or (3) has a minor allele frequency X0.02 in Africans/African-Americans. We also included SNPs with unknown minor allele frequency to provide additional coverage of the gene. All SNPs had to meet suitability criteria for the iPLEX SNP typing assay at the Broad Institute of MIT and Harvard. 19 Overall, 63 SNPs in four CCL genes passed the assay design process; 52 had a call rate of over 90%; and 35 had an minor allele frequency X0.01 (Supplementary Table  S1 ). Table S1 ). SNPs rs1719134 and rs13900 were out of HWE in the overall cohort (The false discovery probability Q values were 0.014 and 0.175, respectively.), but conform to HWE in the HESNs and index subgroups. Genotype frequencies of these two SNPs in the Zambian cohort were quite similar to those reported for other Africans documented in the dbSNP database (National Center for Biotechnology Information). Therefore, those few SNPs whose frequencies were out of HWE were most likely due to chance.
Of the few reports on CCL gene variants and HIV-1 disease progression, 13, [21] [22] [23] [24] none of them addressed the association between CCL variants and HIV-1 VL. By linear regression, we tested the effect of the minor SNP allele on chronic-phase VL in index partners and the set-point VL taken at 6 months after the imputed infection date in seroconverters. 11 Carriage of one copy of the C allele of rs5029410 in CCL3 intron 3 was strongly associated with lower VL in the seroconverters (regression b ¼ À0.57 log 10 , P ¼ 4 Â 10
À6
) with adjustment for age and gender. However, this SNP showed no association with VL in index partners (b ¼ 0.05 log 10 , P ¼ 0.46). Index partners did not receive antiretroviral therapy, but their average duration of infection was much longer than that of seroconverters. Thus, the SNP variant might exert its effect only early in HIV-1 infection rather than later.
The A allele of rs34171309 in CCL3 exon 3 was associated with more rapid acquisition of HIV-1 by HESNs, as shown in an allelic proportional hazards model in the presence of non-genetic factors (hazard ratio (HR) ¼ 1.52, 95% CI: 1.13-2.04, P ¼ 0.006; Table 1 ). This association was also apparent in logistic regression model: the frequency of rs34171309A was higher in the seroconverters (SCs) than HESNs (odds ratio ¼ 1.51, P ¼ 0.05). In Kaplan-Meier plots, differences were seen in HESNs and female HESNs (Figure 1) .
The alleles defining rs34171309 encode a non-synonymous Glu-to-Asp amino acid change at position 78 in the CCL3 protein. Although this change is a conservative one, because it occurs very close to the site of CCL3 binding to the CCR5 protein, it may influence CCL3-CCR5 interaction. 25 The A allele of rs34171309 and the C allele of rs5029410 were in weak LD (r 2 ¼ 0.01), but rs34171309A was in LD with five other SNPs (rs1719130, rs1719134, rs35511254, rs1634497 and rs1634499) in CCL3 (r 2 40.4), and all these SNPs had similar associations with HIV-1 acquisition (data not shown). Three of them (rs1719130, rs35511254 and rs1719134) had minor alleles associated with fast HIV-1 disease progression in earlier studies. 21, 26 In an analysis of the initially HESNs stratified by gender, we again found a stronger effect of rs34171309A in the HESN females than in the smaller number of males, but the effect for both groups is in the same direction (female: HR ¼ 1.70, 95% CI: 1.17-2.47, P ¼ 0.006; male: HR ¼ 1.29, 95% CI: 0.78-2.15, P ¼ 0.33). This difference in significance may be due to an interaction between this SNP and gender or simply to chance variation. Abbreviations: CCL, CC-motif chemokine ligand; CI, confidence interval; GUI, genital ulcer/inflammation; HESN, HIV-1 exposed seronegative; HR, hazard ratio; VL, plasma HIV-1 viral load (RNA copies per ml). For the two SNPs highlighted in this study, genotypes for one (rs5029410) were validated by a TaqMan genotyping assay (Applied Biosystems, Inc., Carlsbad, CA, USA). Selective tests revealed over 98% concordance rate between TaqMan and iPLEX results. For rs34171309, however, variants could not be readily validated by alternative techniques. Based on alignments of homologous sequences from CCL3, CCL3L1 and CCL3L3 genes (Supplementary Figure S2) , only CCL3 was polymorphic at the nucleotide position corresponding to rs34171309. As a result, we infer that rs34171309A is most likely present in CCL3 and not in its homologues.
At the CCL5 locus, one SNP variant known as In1.1C (rs2280789) has been associated with higher risk of HIV-1 subtype B infection in Europeans and African-Americans and with more rapid HIV-1 disease progression in African-Americans. 6 In our study population, no such association could be established for In1.1C or its haplotypes. In particular, In1.1C had no association with HIV-1 acquisition (HR ¼ 1.05, 95% CI: 0.84-1.31, P ¼ 0.70).
We did not adjust P-values for the number of tests implied by the number of SNPs eligible for analysis, because a number of SNPs within each gene are in high LD with each other and the number of independent tests would actually be considerably lower. Only the strong association of rs5029410C (CCL3 intron 3 variant) would have withstood even conservative Bonferroni correction. The false discovery probability (Q value) for rs5029410C and rs34171309A was 0.0001 and 0.03, respectively.
Compared with data from commercially available genome-wide association chip arrays or open access databases, our study provided denser coverage of the variation in all four CCL genes studied. The seven SNPs in CCL3 span a 5-kb genomic region. In contrast, both the Human1M-Duo DNA Analysis BeadChip (Illumina, Inc., San Diego, CA, USA) and the GeneChip Human SNP 6.0 Assay (Affymetrix, Inc., Santa Clara, CA, USA) target a single SNP in CCL3. Patterns of LD, as determined for 35 CCL SNPs in our study population, may help to guide future research on African cohorts, because even the latest HapMap Phase II þ III dataset (released on 28 August 2010) only reports 19 SNPs in the four CCL genes studied here.
In summary, we systematically screened SNPs in the genes encoding three principal natural ligands of CCR5 (HIV-1 coreceptor) and in the adjacent gene CCR2. Data from a large prospective cohort of HIV-1 serodiscordant couples enabled us to test SNP associations with both HIV-1 acquisition and early or chronic-phase VL in a high-risk study population. Overall, two variants in CCL3 and none in other genes relevant to CCR5 or CCR2 function appeared to influence early events in the natural history of HIV-1 infection, either by altering the rate of HIV-1 infection in HESN partners or by modulating HIV-1 VL soon after seroconversion. Future functional studies of these SNPs may fully resolve their potential effects on HIV-1 acquisition and control. 
